| 6.0288 -0.061 (-1%) | 07-31 13:34 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.48 | 1-year : | 7.84 |
| Resists | First : | 6.4 | Second : | 6.71 |
| Pivot price | 6.05 |
|||
| Supports | First : | 5.9 | Second : | 4.9 |
| MAs | MA(5) : | 6.02  |
MA(20) : | 6.12 |
| MA(100) : | 5.86 |
MA(250) : | 5.68 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 32.6 |
D(3) : | 24.6 |
| RSI | RSI(14): 47.6 |
|||
| 52-week | High : | 9.39 | Low : | 3.79 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ HBIO ] has closed above bottom band by 36.9%. Bollinger Bands are 75.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 31 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 6.11 - 6.14 | 6.14 - 6.17 |
| Low: | 5.87 - 5.92 | 5.92 - 5.96 |
| Close: | 6.02 - 6.09 | 6.09 - 6.15 |
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through websites and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic laboratories. It primarily sells its products under the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS, Warner, DSI, Panlab, Hugo Sachs, and Buxco brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
Thu, 30 Jul 2026
Harvard Bioscience Inc (HBIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Thu, 30 Jul 2026
HBIO|Harvard Bioscience Inc|Price:6.000|Chg%:+0.080 - TradingKey
Tue, 28 Jul 2026
Harvard Bioscience to release quarter results before market opens Aug. 11 - Stock Titan
Tue, 28 Jul 2026
Harvard Bioscience Schedules Second Quarter 2026 Earnings Conference Call for August 11, 2026 at 8:00 AM ET - GlobeNewswire
Tue, 28 Jul 2026
Harvard Bioscience Inc (HBIO) Institutional Confidence - TradingKey
Sun, 26 Jul 2026
Harvard Bioscience Inc (HBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 5 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 9.4 (%) |
| Held by Institutions | 41.4 (%) |
| Shares Short | 56 (K) |
| Shares Short P.Month | 89 (K) |
| EPS | -2.16 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.23 |
| Profit Margin | -11.5 % |
| Operating Margin | -4.6 % |
| Return on Assets (ttm) | 1.7 % |
| Return on Equity (ttm) | -78.7 % |
| Qtrly Rev. Growth | -4.7 % |
| Gross Profit (p.s.) | 11.07 |
| Sales Per Share | 18.96 |
| EBITDA (p.s.) | 1.73 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 3 (M) |
| Levered Free Cash Flow | 8 (M) |
| PE Ratio | -2.8 |
| PEG Ratio | 1.3 |
| Price to Book value | 2.69 |
| Price to Sales | 0.31 |
| Price to Cash Flow | 8.8 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|